Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-Year results from the randomised controlled trial IMAGE

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 351-357

  Tak, Paul P ^a   Rigby, William ^b   Rubbert Roth, Andrea ^c   Peterfy, Charles ^d   Van Vollenhoven, Ronald F ^e   Stohl, William ^f   Healy, Emma ^g   Hessey, Eva ^g   Reynard, Mark ^g   Shaw, Tim ^g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Spire Sciences LLC   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB;

ARTHROPATHY; ARTICLE; BRAIN INFARCTION; CANDIDIASIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DUODENUM ULCER; FUNCTIONAL ASSESSMENT; HUMAN; JOINT DAMAGE; JOINT FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857233786     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200170     Document Type: Article

References (24)

1. Yelin E, Trupin L, Wong B, et al. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7. (Pubitemid 34988692)
2. Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42. (Pubitemid 36682360)
3. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
5. van der Heijde D, Landewé R, van Vollenhoven R, et al. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.
6. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
7. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
8. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49:1683-93.
9. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
10. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
11. Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-61.
12. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
13. Rigby W, Ferraccioli G, Greenwald M, et al. Rituximab improved physical function and quality of life in patients with rheumatoid arthritis naïve to methotrexate (IMAGE study). Arthritis Care Res (Hoboken) 2010. In press.
14. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75(6A):35-47. (Pubitemid 14183619)
15. Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90. (Pubitemid 28459916)
16. Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005;52:1637-41. (Pubitemid 40852869)
17. Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011. In press.
18. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
19. Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63:933-8.
20. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
21. Chatzidionysiou K, Lie E, Lukina G, et al. Efficacy and safety of rituximab treatment in clinical practice: data from the CERERRA collaboration. Ann Rheum Dis 2011;70:1575-80.
22. van Vollenhoven R, Emery P, Bingham CO III, et al. Long-term safety of rituximab: follow-up of the rheumatoid arthritis clinical trials and retreatment population. Arthritis Rheum 2010;62(Suppl 10):S165.
23. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
24. US FDA Safety Information available at http://www.fda.gov/downloads/ Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM187792.pdf (accessed 26 September 2011)